The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 508.00
Bid: 506.00
Ask: 510.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.791%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 508.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

24 Nov 2021 07:00

RNS Number : 3368T
Marlowe PLC
24 November 2021
 

24 November 2021

 

Marlowe plc

 

Trading Update and Notice of Results

 

Marlowe plc ("Marlowe" or the "Group"), the UK leader in business-critical services and software which assure regulatory compliance, provides the following trading update ahead of publication of the Group's interim results for the six months ended 30 September 2021 on 1 December 2021.

 

 

Trading Update and Outlook

 

Trading in the first half of the financial year was strong and the Group now expects to report FY 2022 full year results ahead of current market expectations as a result of strong organic growth and the successful execution during FY 2022 to date of our Deepen, Broaden, Strengthen and Digitalise compliance software and service strategy:

 

· H1 FY 2022 Group revenue up 61% to £134.5 million.

· Organic revenue growth of 15%1, 8% when adjusting for COVID impact2

· H1 FY 2022 Divisional adjusted EBITDA3 margin increased 300 bps to 17.8%

· H1 FY 2022 Adjusted EPS up 50% to 16.0p

· H1 FY 2022 Adjusted profit before tax up 127% to £15.2 million

 

A Record Period for Acquisitions

 

· Twelve acquisitions completed during H1 FY 2022 for a total initial consideration of £76.5 million, adding approximately £11.4 million of adjusted EBITDA3

· Three software acquisitions increasing SaaS annual recurring revenues to c.£35 million, in line with Digitalise strategy

· Four acquisitions completed so far in H2 FY 2022, deploying total initial consideration of £95.5 million, adding approximately £9.4 million of adjusted EBITDA3

 

Current group run rate annualised revenue is c. £335 million and run rate annualised adjusted EBITDA3 is approximately £60 million.

 

The second half of the financial year has started well, with strong demand experienced across the business, the integration programmes of all completed acquisitions remaining on track with synergies being achieved in line with expectations. In addition, the Group's pipeline of earnings-enhancing acquisitions is buoyant.

 

The Group now expects to materially overachieve against FY 2024 target run rate revenue of c.£500 million and adjusted EBITDA3 of c.£100 million.

 

1 Organic revenue growth % on a like-for-like basis is defined as the year-on-year growth of our entire business. This includes the growth or decline of acquisitions from the day of completion, by including their performance for the corresponding prior period.

2 Organic growth is adjusted by an estimated (7)% to reflect the COVID impact on TIC division in prior year - minimal impact was experienced in GRC division.

3 Earnings before interest, taxes, depreciation, and amortisation ("EBITDA")

 

 

Notice of Half Year Results and Investor Presentation

 

Marlowe intends to announce its unaudited half year results for the period ended 30 September 2021 on 1 December 2021. Marlowe will host a virtual Half Year Results for investors and equity analysts on 1 December at 09:00 GMT.

 

A link to the event is here.

 

A video replay of the presentation will be available through the Marlowe website post-event. 

 

 

For further information:

 

Marlowe plc

www.marloweplc.com

Alex Dacre, Chief Executive

Tel: +44 (0) 203 841 6194

Adam Councell, Chief Financial Officer

IR@marloweplc.com

Julian Wais, Head of Investor Relations

 

 

 

Cenkos Securities plc - Nominated Adviser & Joint Broker

Nicholas Wells

Tel: +44 (0)20 7397 8900

Ben Jeynes

 

George Lawson

 

 

 

Joh. Berenberg, Gossler & Co. KG, London Branch - Joint Broker

Mark Whitmore

Ben Wright

Dan Gee-Summons

Tel: +44 (0)20 3207 7800

 

FTI Consulting

Nick Hasell

Tel: +44 (0)20 3727 1340

Alex Le May

 

 

About Marlowe plc

 

Marlowe is a UK leader in business-critical services and software which assure regulatory compliance. The company was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated safety and compliance services and software. It is focused on compliance software, eLearning, health & safety, employment law & HR compliance, fire safety & security, water & air hygiene and occupational health services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides software to over 1 million users and services to over 25% of Britain's commercial premises. The Group provides customers with a single outsourced, nationwide, provider of a range of regulated compliance and safety solutions. Our customers can be found in office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (as amended), which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018. Upon publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGZMZMLFVGMZM
Date   Source Headline
11th Oct 20221:40 pmRNSHolding(s) in Company
10th Oct 20222:06 pmRNSHolding(s) in Company
21st Sep 20224:18 pmRNSHolding(s) in Company
20th Sep 20222:02 pmRNSHolding(s) in Company
14th Sep 202211:56 amRNSResult of Annual General Meeting
14th Sep 20227:00 amRNSAGM Statement
2nd Sep 20229:41 amRNSHolding(s) in Company
30th Aug 20227:00 amRNSLaunch of Group 2022 SAYE Scheme
16th Aug 20223:38 pmRNSExercise of Share Options and Total Voting Rights
9th Aug 20227:00 amRNSPublication of Notice of AGM and Annual Report
8th Aug 20227:00 amRNSChange of Auditor
7th Jul 20225:14 pmRNSDirector/PDMR Shareholding
5th Jul 20222:24 pmRNSExercise of Share Options and Total Voting Rights
4th Jul 20223:54 pmRNSExercise of Share Options and Total Voting Rights
4th Jul 20222:10 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSPublication of Annual Report
28th Jun 20227:00 amRNSFinal Results
23rd Jun 20227:00 amRNSNotice of Full Year Results Analyst Presentation
8th Jun 20227:00 amRNSAcquisition of HR Solutions
25th May 20227:00 amRNSAcquisition of Cedrec Information Systems Limited
23rd May 202212:55 pmRNSExercise of Share Options and Total Voting Rights
28th Apr 20224:22 pmRNSHolding(s) in Company
28th Apr 20224:18 pmRNSHolding(s) in Company
26th Apr 20224:36 pmRNSExercise of Share Options and Total Voting Rights
19th Apr 20227:00 amRNSAcquisition of TP Health
11th Apr 202210:47 amRNSExercise of Share Options
5th Apr 20223:05 pmRNSCapital Markets Day Replay
5th Apr 20227:00 amRNSCapital Markets Day
22nd Mar 20227:00 amRNSAcquisition of Griffin Fire
21st Mar 20227:00 amRNSNotice of Capital Markets Day and Trading Update
15th Mar 20227:00 amRNSAppointment of Joint Corporate Broker
17th Feb 20227:00 amRNSDirectorate Change
11th Feb 20227:00 amRNSAcquisition of S F Fire Limited
10th Feb 20227:00 amRNSNew Enlarged Debt Facility
31st Jan 202212:20 pmRNSHolding(s) in Company
28th Jan 20222:19 pmRNSDirector/PDMR Shareholding
27th Jan 20229:07 amRNSHolding(s) in Company
26th Jan 202211:39 amRNSDirector/PDMR Shareholding
26th Jan 20227:00 amRNSIssue of Equity and Total Voting Rights
21st Jan 20221:08 pmRNSHolding(s) in Company
20th Jan 20224:08 pmRNSResults of Placing
20th Jan 20227:48 amRNSProposed Placing and Acquisition of Optima Health
20th Jan 20227:00 amRNSAcquisition of Optima Health
19th Jan 202212:13 pmRNSAppointment of Independent Non-Executive Director
14th Jan 20225:01 pmRNSExercise of Share Options
20th Dec 20217:00 amRNSAcquisition of Skill Boosters
14th Dec 202111:12 amRNSHolding(s) in Company
1st Dec 20212:00 pmRNSHalf Year Results Presentation Replay
1st Dec 20217:00 amRNSHalf Year Results
24th Nov 20217:00 amRNSTrading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.